This is a prospective, multicenter observational trial for patients who develop critical illness after hematopoietic cell transplantation. Patients who are admitted to the intensive care unit after undergoing hematopoietic cell transplantation at the participating medical centers will be enrolled in this study. The clinical characteristics, laboratory profiles, managements, and clinical outcomes will be prospectively collected.
Patients who underwent hematopoietic cell transplantation at any of the participating medical centers.
Patients who are admitted to ICU for the management of critical illness following hematopoietic cell transplantation.
Admitted to ICU for a reason other than critical illness (e.g., routine postoperative monitoring) and discharged within 2 days of ICU admission.
Unavailable in-ICU clinical outcomes or absent key baseline characteristics.
Any other conditions that, in the opinion of the investigator, can interfere with the interpretation of data.
Patients who are admitted to ICU after undergoing hematopoietic cell transplantation at any of the participating medical centers.
Cohort
Prospective
Not listed
Overall survival
Overall survival after admission to the intensive care unit.
Non-relapse mortality
Non-relapse mortality after ICU admission.
Relapse
Disease relapse or progression at or after ICU admission.
Transplant complication
Hematopoietic-cell-transplantation-associated complications at or after ICU admission.
Organ failure
Organ failure occurring at or after ICU admission.
Click on the lead sponsor to view all of their trials.
Peking University People's Hospital
Lead sponsor
Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences)
Collaborator
Xinqiao hospital of the third military medical university
Collaborator
First Affiliated Hospital of Zhejiang University
Collaborator
First Affiliated Hospital of Harbin Medical University
Collaborator
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
